Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
66.62
+0.39 (0.59%)
At close: Dec 5, 2025, 4:00 PM EST
71.71
+5.09 (7.64%)
After-hours: Dec 5, 2025, 7:52 PM EST
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $2.76M in the quarter ending September 30, 2025, a decrease of -26.12%. This brings the company's revenue in the last twelve months to $43.74M, down -50.05% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$43.74M
Revenue Growth
-50.05%
P/S Ratio
124.96
Revenue / Employee
$232,633
Employees
188
Market Cap
4.79B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KYMR News
- 1 day ago - Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 - GlobeNewsWire
- 3 days ago - Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewsWire
- 12 days ago - Kymera Therapeutics to Participate in Upcoming December Investor Conferences - GlobeNewsWire
- 26 days ago - Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Kymera Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 5 weeks ago - Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire